ADmit Therapeutics Closes a Round of €5.4 Million for Its Technology Against Alzheimer’s

ADmit Therapeutics increases capital. The Spanish company has announced the closing of a financing round of €5.4 million led by the Clave Innohealth fund, with the aim of developing and commercializing a new technology for the early detection of Alzheimer’s. The round also included participation from the EIC Fund and Alzheimer’s Drug Discovery Foundation, as well as investors Lavanda Ventures, Ship28, and WA4Steam.

The firm has assured that the capital raised will allow it to obtain validation from the European Commission (EC) and the US Food and Drug Administration (FDA) to begin the commercialization of its technology against Alzheimer’s both in Europe and in the United States.

This new technology makes it easier for pharmaceutical companies to “optimize patient selection and reduce both the time and costs associated with clinical trials, increasing the possibility of identifying new effective therapies for Alzheimer’s,” as highlighted by the company in a statement.

If you want to read more about ADmit Therapeutics and to find the most important financial news of the day, download for free our companion app Born2Invest.

ADmit Therapeutics wants to obtain approval to commercialize the technology in both Europe and the United States

Marta Barrachina, executive director of ADmit, has pointed out that “our proposal allows, through a blood sample and using next-generation sequencing techniques, to calculate the probability of progression of a patient with mild cognitive impairment to Alzheimer’s dementia. ” The directive added that “this makes it easier for clinicians to optimally stratify patients and prescribe the best treatment.”

Founded in 2017, Admit Therapeutics is a spin-off of the Bellvitge Biomedical Research Institute (Idibell), which specializes in the development of an in vitro diagnostic device to detect Alzheimer’s early. Specifically, the Catalan company is developing a test that uses sequencing and a machine learning approach to measure methylation changes in mitochondrial DNA that can predict progression towards Alzheimer’s disease dementia.

Clave Capital is an independent investment manager in alternative assets specializing in innovative projects and industrial SMEs. Currently, it manages more than ninety million euros aimed at innovative projects, highlighting the fifty million Clave Innohealth fund, promoted with the support of Cdti Innvierte and several private investors linked to the health sector.

__

(Featured image by Public Domain Pictures via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.